We followed 141 patients treated with imatinib mesylate (> 300 mg) for chronicphase chronic
myelogenous leukemia (CML) following failure of treatment with interferon. During 12 …

Residual disease in chronic myeloid leukemia patients may be assessed by various
molecular methods. After imatinib treatment a significant proportion of patients achieve …

Achieving a molecular response after imatinib treatment is considered today the gold
standard on Ph+ CML therapy. However, only a restrict group of patients is able to achieve a …

Clinical introduction of imatinib mesylate (Gleevec)(formerly STI571) has marked a major
advance in the treatment of chronic myeloid leukemia (CML), inducing major cytogenetic …

Resistance to imatinib can arise through point mutations in the ABL kinase domain or BCR-
ABL gene amplification (reviewed in Gambacorti-Passerini et al1), by activation of the efflux …

Abstract BACKGROUND. Interferon‐alpha (IFN‐α) confers a survival advantage for the
minority of patients with chronic myeloid leukemia (CML) who achieve a complete …

e16612 Background: For patients with chronic myeloid leukemia (CML) who achieve major
molecular response (MMolR), long-term disease-free survival is possible, as well as a lower …

The introduction of imatinib has significantly changed prognosis of CML patients. Despite
favourable hematologic and cytogenetic response (CyR) data, patients (pts) on first line …

Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have
become the standard therapy for chronic myeloid leukaemia (CML). While allogeneic …

Background: Imatinib is the first line drug therapy for patients with chronic myeloid leukemia
(CML). Drug resistance, after an initial response, is frequently due to reactivation of the BCR …